Bisoprolol

CAS No. 66722-44-9

Bisoprolol( —— )

Catalog No. M24680 CAS No. 66722-44-9

Bisoprolol is a cardioselective β1-adrenergic blocker used for secondary prevention of heart failure, myocardial, angina pectorisinfarction (MI) and mild to moderate hypertension.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 49 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Bisoprolol
  • Note
    Research use only, not for human use.
  • Brief Description
    Bisoprolol is a cardioselective β1-adrenergic blocker used for secondary prevention of heart failure, myocardial, angina pectorisinfarction (MI) and mild to moderate hypertension.
  • Description
    Bisoprolol is a cardioselective β1-adrenergic blocker used for secondary prevention of heart failure, myocardial, angina pectorisinfarction (MI) and mild to moderate hypertension.(In Vitro):Bisoprolol hemifumarate (2 μM, 1 h) protects myocardial cells (H9c2) from ischemia/reperfusion (I/R) injury.Bisoprolol hemifumarate (2 μM, 1 h) reduces the H/R-induced ROS production and apoptosis in H9c2 cells.Bisoprolol hemifumarate (2 μM, 1 h) increases AKT and GSK3β phosphorylation in H9c2 cells.Bisoprolol hemifumarate (100 μM, 24 h) reverses Epinephrine-inhibited emigration in cholesterol-loaded DCs (dendritic cell) through increasing in β-arrestin 2, CCR7 and PI3K phosphorylation.(In Vivo):Bisoprolol hemifumarate (oral administration, 5 mg/kg, for 1 week) increases left ventricular ejection fraction (LVEF) and decreases the heart rate value.Bisoprolol hemifumarate (oral gavage, 8 mg/kg, daily for four weeks) shows protective effects against Cadmium-induced myocardial toxicity in rats.Bisoprolol hemifumarate (oral gavage, 1 mg/kg, daily for 6 weeks) reversessmall conductance calcium-activated potassium channel (SK) remodeling in a volume-overload rat model.
  • In Vitro
    Bisoprolol (2 μM, 1 h) protects myocardial cells (H9c2) from ischemia/reperfusion (I/R) injury.Bisoprolol (2 μM, 1 h) reduces the H/R-induced ROS production and apoptosis in H9c2 cells.Bisoprolol (2 μM, 1 h) increases AKT and GSK3β phosphorylation in H9c2 cells.Bisoprolol (100 μM, 24 h) reverses Epinephrine-inhibited emigration in cholesterol-loaded DCs (dendritic cell) through increasing in β-arrestin 2, CCR7 and PI3K phosphorylation. Cell Viability Assay Cell Line:H9c2 cells Concentration:0.2, 2, 20 μM Incubation Time:1 h Result:Elevated the survival rates of cardiomyocytes subjected to H/R (hypoxia/reoxygenation) to 73.20%, 90.38%, 81.25% respectively.Cell Migration Assay Cell Line:DCs Concentration:100 μM Incubation Time:6, 12, 24 h Result:Increased the amount of migrating cells by 46.00% (6 h), 64.25% (12 h) and 55.74% (24 h).
  • In Vivo
    Bisoprolol (oral administration, 5 mg/kg, for 1 week) increases left ventricular ejection fraction (LVEF) and decreases the heart rate value.Bisoprolol (oral gavage, 8 mg/kg, daily for four weeks) shows protective effects against Cadmium-induced myocardial toxicity in rats.Bisoprolol (oral gavage, 1 mg/kg, daily for 6 weeks) reverses small conductance calcium-activated potassium channel (SK) remodeling in a volume-overload rat model. Animal Model:Ischemia/reperfusion (I/R) injury rats Dosage:0.5, 5, 10 mg/kg Administration:Oral administration, for 1 week, prior to 0.5 h ischemia/4 hreperfusion.Result:Reduced infarct size from 44% in I/R group to 31% in treated group.Animal Model:Cadmium-induced rats Dosage:2, 8 mg/kg Administration:Oral gavage, daily for four weeks.Result:Decreased mean arterial pressure (MAP) at 8 mg/kg.Decreased serum biomarkers (ALT, AST) and NF-kB p65 expression and TNF-α levels (cardiac tissue samples) at 8 mg/kg.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Adenosine Receptor
  • Recptor
    β1-adrenergic receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    66722-44-9
  • Formula Weight
    325.44
  • Molecular Formula
    C18H31NO4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    OC(CNC(C)C)COC1=CC=C(COCCOC(C)C)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • GS-6201

    GS-6201 is a selective antagonist of adenosine A2B receptor. GS-6201 shows high affinity and selectivity for the human adenosine A2B receptors with a Ki of 22 nM.

  • Labetalol

    Labetalol is a mixed alpha/beta-adrenergic antagonist.It is used to treat high blood pressure. It can be given by mouth for long term hypertension management or intravenously in severe hypertensive situations. The pharmacokinetics of labetalol is affected by the common CYP2C19 polymorphisms.

  • LUF6000

    LUF6000 is a potent, selective, positive allosteric modulator (enhancer) of human A3 adenosine receptor.